Patents Assigned to GUANGZHOU PHARMACEUTICAL INDUSTRIAL RESEARCH INSTI
  • Publication number: 20140128359
    Abstract: The invention relates to N-heterocyclic substituent-containing antibiotics, their preparation, and their use. Disclosed are sodium and potassium salts of 7-(?-((N,N?-diisopropylamidino)thio)acetylamino)-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-diox o-1,2,4-triazin-3-yl)thio)methyl) cephalosporanic acid as presented by the general structure (I), their preparation, and their use. The antibiotics of the invention can be used to treat diseases caused by Gram-positive or Gram-negative bacteria such as septicaemia, gastrointestinal tract infection, and urinary tract infection. They have increased half-life in blood and lowered toxicity. They can reduce the frequency of drug use and lower medical treatment costs. They have improved stability and can be stored at ambient temperatures. The method of the invention is simple, and it produces high purity products which can meet the requirements of clinical use.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 8, 2014
    Applicants: GUANGZHOU PHARMACEUTICAL INDUSTRIAL RESEARCH INSTI, GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO., LTD. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY
    Inventors: Mao Chen, Shaoxuan Zhu, Xuebin Liu, Lizhen Zheng, Liwei Lin, Shuwen Xu, Yuping Wang, Wei Yang, Yunfeng Li, Fang Ye, Xiaona Zhang
  • Publication number: 20110118462
    Abstract: The invention relates to N-heterocyclic substituent-containing antibiotics, their preparation, and their use. Disclosed are sodium and potassium salts of 7-(?-((N,N?-diisopropylamidino)thio)acetylamino)-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio)methyl) cephalosporanic acid as presented by the general structure (I), their preparation, and their use. The antibiotics of the invention can be used to treat diseases caused by Gram-positive or Gram-negative bacteria such as septicaemia, gastrointestinal tract infection, and urinary tract infection. They have increased half-life in blood and lowered toxicity. They can reduce the frequency of drug use and lower medical treatment costs. They have improved stability and can be stored at ambient temperatures. The method of the invention is simple, and it produces high purity products which can meet the requirements of clinical use.
    Type: Application
    Filed: November 18, 2009
    Publication date: May 19, 2011
    Applicants: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO., LTD. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL FACTORY, GUANGZHOU PHARMACEUTICAL INDUSTRIAL RESEARCH INSTI
    Inventors: Mao CHEN, Shaoxuan Zhu, Xuebin Liu, Lizhen Zheng, Liwei Lin, Shuwen Xu, Yuping Wang, Wei Yang, Yunfeng Li, Fang Ye, Xiaona Zhang